Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21693640 | 0.83 | DGAT1 (0.33) | DGAT1CA12CA2CA14CYP2D6 | |
| SCHEMBL3186705 | 0.80 | CA12 (0.37) | DGAT1CA12CA2CA14CYP2D6 | |
| SCHEMBL27963219 | 0.79 | STING1 (0.34) | DGAT1CA12CA2CA14CYP2D6 | |
| SCHEMBL234057 | 0.79 | TSHR (0.43) | CA12CA2CYP2D6L3MBTL1 | |
| SCHEMBL15438423 | 0.79 | ELANE (0.38) | — | |
| SCHEMBL12567220 | 0.77 | CYP2D6 (0.37) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL799524 | 0.77 | DGAT1 (0.33) | DGAT1CA12CA2CA14CYP2D6 | |
| SCHEMBL2198384 | 0.77 | MEN1 (0.40) | DGAT1CA12CA2CA14CYP2D6 | |
| SCHEMBL8563170 | 0.77 | ALDH1A1 (0.36) | LMNA | |
| SCHEMBL991 | 0.77 | TSHR (0.46) | CA12CA14L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119409581-A | Preparation method of milabalin | 济宁学院 | 2025-02-11 | — | — | CN | claimed |
| CN-117447355-B | Preparation method of milbelin intermediate | 南京威凯尔生物医药科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-112384493-B | Process for preparing fused tricyclic gamma-amino acid derivatives and intermediates | 四川海思科制药有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-112384493-A | Process for the preparation of fused tricyclic gamma-amino acid derivatives and intermediates | 四川海思科制药有限公司 | 2021-02-19 | — | — | CN | claimed |
| WO-2020029762-A1 | PREPARATION METHOD FOR FUSED TRICYCLIC γ-AMINO ACID DERIVATIVE AND INTERMEDIATE THEREOF | 四川海思科制药有限公司 | 2020-02-13 | — | — | WO | claimed |
| EP-4695262-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688788-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034098-A1 | BRIDGED TRICYCLIC GABA DERIVATIVES AS CALCIUM CHANNEL MODULATORS, METHODS OF MAKING AND METHODS OF USING THEREOF | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2026-02-05 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-12295947-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | RAQUALIA PHARMA INC. (JP) | 2025-05-13 | — | — | US | disclosed |
| US-5457118-A | Pyridine derived agents for cardiovascular diseases | PFIZER INC. (US) | 1995-10-10 | — | — | US | disclosed |
| US-5426103-A | Endopeptidase inhibitors; condensing macrocylic compound with a thioic acid or salt therof; possible esterification, salt formation, deslating, deprotecting, deesterifying of function-al groups | CIBA-GEIGY CORPORATION (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0579618-A1 | PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES | Pfizer Limited (GB) | 1994-01-26 | — | — | EP | disclosed |
| US-5244889-A | Treatment of cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0544620-A1 | Macrocyclic lactams as inhibitors of atrial natriuretic factors (ANF)-degrading neutral endopeptidase (NEP) | CIBA-GEIGY AG (CH) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992017451-A1 | PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES | PFIZER LIMITED (GB) | 1992-10-15 | — | — | WO | disclosed |
| US-4937331-A | Chemical intermediates for antibiotics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1990-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | DGAT1 4152/4885CA12 1955/4885CA2 1172/4885 |
| US-20260034098-A1 | BRIDGED TRICYCLIC GABA DERIVATIVES AS CALCIUM CHANNEL MODULATORS, METHODS OF MAKING AND METHODS OF USING THEREOF | GABRB2, GABRB1, GABRB3 | DGAT1 2872/4885CA12 1156/4885CA2 103/4885 |
| US-12295947-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | DGAT1 3883/4885CA12 4633/4885CA2 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.